iRadimed (IRMD) vs Profound Medical (PROF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
iRadimed (IRMD) has outperformed Profound Medical (PROF) over the past year, gaining 16.0% versus a gain of 4.1%. Over five years, IRMD leads with a +138.5% price change compared with -54.0% for PROF. iRadimed is the larger company by market cap ($1.12 billion vs $252.1 million), about 4.4 times the size.
iRadimed pays a dividend yielding 0.88%, while Profound Medical does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRMD | PROF |
|---|---|---|
| Share price | $87.45 | $6.90 |
| Market cap | $1.12B | $252.13M |
| 1-day change | +1.83% | -0.14% |
| YTD return | -10.10% | -12.33% |
| 1-year return | +15.95% | +4.07% |
| 5-year return | +138.48% | -54.03% |
| P/E ratio (TTM) | 48.85 | — |
| Forward P/E | 35.65 | — |
| EPS (TTM) | $1.79 | $-0.99 |
| Dividend yield | 0.88% | 0.00% |
| Annual dividend | $0.77 | $0.00 |
| Revenue (latest FY) | $83.81M | — |
| Revenue growth (YoY) | +14.43% | — |
| Net income (latest FY) | $22.48M | — |
| Gross margin | 76.75% | — |
| Operating margin | 31.20% | — |
| Net margin | 26.82% | — |
| 52-week high | $107.90 | $8.95 |
| 52-week low | $71.34 | $4.80 |
| Distance from 52-week high | -18.95% | -22.91% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +34.93% | +61.45% |
| Average volume | 125.83K | 168.50K |
| Shares outstanding | 12.79M | 36.54M |
| Employees | 166 | 162 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- iRadimed is about 4.4 times larger than Profound Medical by market value ($1.12B vs $252.13M).
- IRMD has outperformed PROF by 11.9 percentage points over the past year.
About iRadimed
IRMD stock →IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Healthcare · Medical Devices · 166 employees
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Healthcare · Medical Devices · 162 employees
IRMD vs PROF FAQ
Which is bigger, iRadimed or Profound Medical?
iRadimed (IRMD) is larger, with a market capitalization of $1.12B compared with $252.13M for Profound Medical (PROF).
Which stock has performed better over the past year, IRMD or PROF?
IRMD returned +15.95% over the past 12 months, compared with +4.07% for PROF (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, iRadimed or Profound Medical?
iRadimed pays a dividend yielding 0.88%, while Profound Medical does not currently pay a regular dividend.
Are iRadimed and Profound Medical in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.